A phase I clinical trial to study the safety of treatment with Tipifarnib (ZARNESTRA) combined with Bortezomib (VELCADE) in patients with myelodysplastic syndrome (MDS) - Bortezomib and Tipifarnib in MDS

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 18 人开始时间: 待定最近更新: 2024年6月18日

适应症

试验速览

暂无简介。

•MDS (including the non-proliferative form of CMML, i.e. CMML with a WBC count < 12,0 x 109) /L with < 30% blast cells in the bone marrow and with < 5% circulating blasts).
•IPSS score: Intermediate Risk-2 or High Risk
•Age at the time of obtaining informed consent 18 years or older
•WHO performance status 0-2

•IPSS score: low risk and intermediate-1 category.
•Candidates for allogeneic stem cell transplantation.
•Clinical relevant liver (AST/ALT equal to or higer than 1,5 ULN and bilirubin equal to or higher than 2 mg/dl) or renal insufficiency (ECC < 50 %).
•Significant vascular, pulmonary, gastrointestinal, endocrine, rheumatologic, or metabolic disturbances.
•Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment.
•Receipt of extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy within 8 weeks before enrollment.
•Having received a stem cell transplantation.

发起方

niversitair Medisch Centrum Sint Radboud